Author: Nick Mulcahy
The U.S. Food and Drug Administration has approved the first biosimilar to pegfilgrastim (Neulasta, Amgen), a granulocyte colony-stimulating factor used to reduce infection risk in patients with cancer.
The new product is pegfilgrastim-jmdb ( Fulphila , Mylan GmbH), approved for use to decrease the risk for infection in patients with nonmyeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
“Bringing new biosimilars to patients is a top priority for the FDA, and a key part of our efforts to help promote competition that can reduce drug costs and promote access,” said FDA Commissioner Scott Gottlieb, MD, in a press statement.
“We’ll continue to prioritize reviews of these products to help ensure that biosimilar medications are brought to the market efficiently and through a process that makes certain that these new medicines meet the FDA’s rigorous standard for approval,” he added.
The FDA’s approval of pegfilgrastim-jmdb is based on review of evidence that does not include randomized clinical trial data. Instead the evidence consists of structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data.
The most common side effects of pegfilgrastim-jmdb are bone pain and pain in extremities, according to the FDA.
Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as pegfilgrastim or filgrastim products, should not receive pegfilgrastim-jmdb.
Serious side effects from treatment include rupture of the spleen, acute respiratory distress syndrome, serious allergic reactions (including anaphylaxis), glomerulonephritis, leukocytosis, capillary leak syndrome, and the potential for tumor growth. Deaths due to sickle cell crises have occurred with the product.
– GDMeds, an India Pharmacy Service company
- [Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
- [免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作，需遵守第三方的版权，特别是标示为第三方内容的。如用户发现侵犯版权的行为，请通知极得美。一旦收到违反通知，极得美将立刻移除相关内容。
- [отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.